{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:12:54Z","timestamp":1780791174230,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.atherosclerosis.2025.120229","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:46:32Z","timestamp":1748259992000},"page":"120229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry"],"prefix":"10.1016","volume":"408","author":[{"given":"Ruben J.M.","family":"Mijnster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke W.C.M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.H.","family":"Galema-Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mattace-Raso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majon","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Lafeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9493","key":"10.1016\/j.atherosclerosis.2025.120229_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2025.120229_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19148272","article-title":"Serum cholesterol levels and risk of cardiovascular death: a systematic review and a dose-response meta-analysis of prospective cohort studies","volume":"19","author":"Jung","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120229_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120229_bib4","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120229_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/0929867330666230228120601","article-title":"Efficacy and safety of alirocumab and evolocumab as proprotein convertase subtilisin\/Kexin type 9 (PCSK9) inhibitors in familial hypercholesterolemia: a systematic review and meta-analysis","volume":"31","author":"Ghasempour","year":"2024","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120229_bib6","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s12325-020-01259-4","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials","volume":"37","author":"Mu","year":"2020","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120229_bib7","first-page":"Cd011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120229_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2025.120229_bib9","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/eurheartj\/ehz809","article-title":"Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis","volume":"41","author":"Sinnaeve","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120229_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2024.11.019","article-title":"Long-term lipid lowering with evolocumab in older individuals","volume":"85","author":"Al Said","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120229_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12877-022-03279-x","article-title":"Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis","volume":"22","author":"Delara","year":"2022","journal-title":"BMC Geriatr"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2025.120229_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023690","article-title":"Association of low-density lipoprotein cholesterol levels with more than 20-Year risk of cardiovascular and all-cause mortality in the general population","volume":"11","author":"Rong","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"9967","key":"10.1016\/j.atherosclerosis.2025.120229_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(14)60569-9","article-title":"Causes of international increases in older age life expectancy","volume":"385","author":"Mathers","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120229_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jacl.2019.06.006","article-title":"Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies","volume":"13","author":"Raal","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120229_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5202","article-title":"Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review","volume":"3","author":"Khan","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120229_bib16","first-page":"130","article-title":"Anti PCSK9 monoclonal antibody treatment in elderly patients: a real-world clinical experience","volume":"26","author":"Giladi","year":"2024","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.atherosclerosis.2025.120229_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112519","article-title":"PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort","volume":"146","author":"Vicente-Valor","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120229_bib18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jacl.2017.02.014","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience","volume":"11","author":"Galema-Boers","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120229_bib19","series-title":"Ministerie van Volksgezondheid WeS","article-title":"GVS-advies PCSK9-remmers","author":"Nederland","year":"2023"},{"issue":"45","key":"10.1016\/j.atherosclerosis.2025.120229_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120229_bib21","doi-asserted-by":"crossref","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC). Rev Esp Cardiol 2022;75(5):429.","DOI":"10.1016\/j.rec.2022.04.003"},{"key":"10.1016\/j.atherosclerosis.2025.120229_bib22","unstructured":"Specialists FoDM. Dutch guideline cardiovascular risk management (CVRM). 2024."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2025.120229_bib23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120229_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40292-020-00399-6","article-title":"A retrospective chart review evaluating efficacy, tolerability, and cost of proprotein convertase subtilisin\/Kexin type 9 inhibitors (PCSK9i) in older adults","volume":"27","author":"Davis","year":"2020","journal-title":"High Blood Pres Cardiovasc Prev"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120229_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5603\/CJ.a2017.0137","article-title":"Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohort","volume":"25","author":"Saborowski","year":"2018","journal-title":"Cardiol J"},{"key":"10.1016\/j.atherosclerosis.2025.120229_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.953040","article-title":"Optimized treatment of refractory hypercholesterolemia in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia with Alirocumab (OPTIMIZE)","volume":"9","author":"Sudano","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120229_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jacl.2024.09.005","article-title":"Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: an expert clinical consensus from the national lipid association and the American geriatrics society","volume":"19","author":"Bittner","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"10263","key":"10.1016\/j.atherosclerosis.2025.120229_bib28","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502501127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502501127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T08:32:07Z","timestamp":1777192327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502501127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"alternative-id":["S002191502501127X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120229","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120229"}}